# CC-92480-MM-002 (NCT03989414)

> A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03989414
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: CC-92480; Bortezomib; Dexamethasone; Daratumumab; Carfilzomib; Elotuzumab; Isatuximab; Carfilzomib
- Enrollment: 424
- Primary outcome: Recommended Dose
- Primary outcome: Recommended regimen as measured by dose-limiting toxicities
- Primary outcome: Number of participants with Adverse Events (AEs)
- Primary outcome: Overall response rate (ORR)

## Indexed commentary on CC-92480-MM-002 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 3
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cc-92480-mm-002-nct03989414